FluoroPharma

FluoroPharma is a molecular imaging company dedicated to the discovery, development, and commercialization of diagnostic imaging products for the positron emission tomography (PET) market. Its products include CardioPET, a modified fatty acid that provides deep insight into areas of myocardial metabolic dysfunction, used to identify patients undergoing PCI or revascularization and guide interventions, as well as assess CAD in patients unable to exercise. The company’s products also include BFPET, a novel cardiovascular blood flow imaging agent that concentrates in healthy myocardial cells for detecting presumptive CAD in conjunction with stress testing, as well as identifying multi-vessel CAD. Additionally, FluoroPharma has developed VasoPET, which accumulates in inflammatory regions to evaluate patients at risk of acute coronary syndrome or stroke, as well as for treatment following acute cardiac events or strokes. It focuses on the development of PET imaging agents for the detection and assessment of both acute and chronic coronary artery disease (CAD).